高尿酸血症市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、藥物類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球高尿酸血症市場（包括降尿酸藥物和高尿酸血症診斷工具）預計將從 2025 年的 47.8 億美元成長到 2031 年的 71.3 億美元，複合年成長率為 6.89%。

這一成長主要受全球痛風性關節炎患病率上升以及易患代謝性疾病的老年人口不斷成長的推動。此外，生活方式的普遍改變，例如高嘌呤飲食和肥胖率上升，顯著擴大了需要長期藥物治療的患者群體，導致對黃嘌呤氧化酶抑制劑和尿酸排泄促進劑的需求增加。然而，患者對慢性治療的依從性低以及現有第一線藥物的潛在毒性常常阻礙市場擴張。例如，美國風濕病學會報告稱，到2025年，美國因痛風導致的全國平均殘疾調整生命年（DALYs）將比過去20年增加93.7%，凸顯了當前治療策略不足以有效緩解日益加重的負擔。缺乏有效的長期照護對產業構成重大挑戰，因為安全問題和用藥依從性問題阻礙了現有治療方法的推廣應用。

市場促進因素

市場擴張主要歸因於全球痛風和無症狀性尿酸血症發生率的上升，而這又受到全球人口老化和飲食習慣改變的驅動。隨著預期壽命的延長，老年人口不斷成長，導致與腎臟尿酸排泄減少相關的結晶尿酸沉積疾病發生率升高。除了這些人口趨勢外，高嘌呤飲食和久坐生活方式的普遍流行也加速了代謝功能障礙，並擴大了需要藥物治療的患者群體。例如，2025年6月發表在PubMed Central上的一項研究預測，到2050年，老年人痛風的年齡調整盛行率將達到每10萬人3628.85例，這凸顯了對有效治療方案的持續需求。同時，慢性腎臟病(CKD) 和代謝紊亂負擔的加重進一步凸顯了高尿酸血症管理的重要性，因為高尿酸血症既是腎功能障礙的併發症，也是其進展的促成因素。這種緊迫性迫使醫療專業人員在腎臟病診療中優先考慮主動監測和干涉尿酸水平，以防止腎功能進一步惡化並控制心血管風險。 2025 年 11 月的《科學報告》強調了這一重要性，指出 65.6% 的非透析慢性腎臟病病患者存在高尿酸血症。安進公司 2025 年 2 月的報告也印證了這個高需求細分市場的商業性規模。該報告顯示，安進公司針對痛風的標靶治療藥物 KRYSTEXXA 在 2024 年的銷售額達到 12 億美元，顯示其在治療重症和難治性痛風方面具有巨大的市場價值。

市場挑戰

全球高尿酸血症市場成長的主要限制因素是患者對慢性治療依從性普遍較低，而第一線藥物的安全性問題加劇了這個問題。儘管潛在患者群體不斷擴大，但由於許多患者過早停止治療，實際市場成長受到顯著阻礙。這種高停藥率通常是由於高尿酸血症在發作間期無症狀，導致患者低估了每日服藥的必要性。此外，對毒性的擔憂，例如標準黃嘌呤氧化酶抑制劑相關的嚴重皮膚反應和心血管風險，也使處方醫生和患者猶豫不決，導致長期處方有限。這種普遍存在的依從性不足直接影響市場表現，減少了處方箋更新，並降低了治療的實際療效。當治療方案無法有效執行時，患者的治療效果就會停滯不前，阻礙了更有效治療方法的推廣應用。根據美國風濕病學會 (ACR) 2025 年的調查數據，目前降尿酸治療中，患者對建議劑量指南的依從性仍然不足，僅有不到 50%的治療方法完全符合維持目標血清尿酸水平所需的指南。這種利用率的差距意味著目標市場的大部分尚未被充分開發，阻礙了該行業從日益成長的尿酸疾病盛行率中獲益。

市場趨勢

隨著新型選擇性URAT1抑制劑的迅速湧現，痛風治療領域正經歷重大變革。這些抑制劑旨在克服現有黃嘌呤氧化酶抑制劑療效的限制。藥物研發人員正日益重視高效的尿酸排泄促進劑，這些藥物直接靶向腎臟轉運蛋白以促進尿酸排泄，為那些無法透過標準口服療法達到目標血清尿酸水平的患者提供了一種有效的替代方案。這種臨床變革的標誌是新一代候選藥物的研發進展，這些藥物旨在最大限度地提高療效，同時最大限度地降低腎毒性。例如，FierceBiotech在2025年9月報道，Atom Therapeutics公司的新型URAT1抑制劑ABP-671在一項IIb/III期臨床試驗中取得了令人矚目的91%的緩解率，並在第28週時顯著縮小了豆腐的直徑。同時，對於難治性痛風，特別是那些對傳統口服藥物無反應的重症患者，聯合生物製藥聯合治療正成為重要的治療選擇。這一趨勢包括將重組尿酸酶與免疫調節技術結合，以抑制抗藥性抗體的形成並維持治療效果。這些先進治療方法對於快速減少慢性病例中的晶體沉積至關重要，從而防止不可逆的關節損傷。根據《藥學時報》2025年1月刊報道，新型聯合治療SEL-212在高劑量組中顯示出56%的有效率，並將血清尿酸水平維持在6 mg/dL以下，這表明其有望滿足難治性尿酸缺乏症領域的重要未滿足需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球高尿酸血症市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（主要、次要）
  • 藥物類型（黃嘌呤氧化酶抑制劑、非類固醇消炎劑、皮質類固醇、其他）
  • 給藥途徑（口服、注射）
  • 分銷通路（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美高尿酸血症市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲高尿酸血症市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區高尿酸血症市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲高尿酸血症市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲高尿酸血症市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球高尿酸血症市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Takeda Pharmaceutical Company Limited
• AstraZeneca plc
• Horizon Therapeutics plc
• Novartis AG
• Sanofi SA
• Teijin Pharma Limited
• Mylan NV
• Hikma Pharmaceuticals PLC
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The global hyperuricemia market, which includes urate-lowering therapeutics and diagnostic tools for managing elevated serum uric acid, is projected to expand from USD 4.78 billion in 2025 to USD 7.13 billion by 2031, achieving a compound annual growth rate of 6.89%. This growth is primarily fueled by the increasing worldwide prevalence of gouty arthritis and the expanding elderly population, who are more susceptible to metabolic disorders. Furthermore, widespread lifestyle changes, such as diets rich in purines and rising obesity rates, are significantly enlarging the patient pool that requires long-term pharmacological intervention, thus boosting demand for xanthine oxidase inhibitors and uricosuric agents. However, market expansion is frequently impeded by poor patient adherence to chronic therapy and the potential toxicity associated with existing first-line medications. For instance, the American College of Rheumatology reported in 2025 that the national average disability-adjusted life year rate for gout in the United States increased by 93.7% over the previous two decades, underscoring a growing burden that current management strategies have not fully alleviated. This deficiency in effective long-term care presents a significant challenge to the industry, as safety concerns and compliance issues restrict the consistent adoption of available treatments.

Market Driver

The market's expansion is primarily driven by the rising global incidence of gout and asymptomatic hyperuricemia, fueled by an aging global population and evolving dietary patterns. As life expectancy increases, the geriatric population expands, leading to a higher frequency of crystal deposition diseases linked to reduced renal urate excretion. This demographic trend is compounded by the widespread adoption of high-purine diets and sedentary lifestyles, which accelerate metabolic dysfunction and broaden the patient pool requiring pharmacological intervention. A study published in PubMed Central in June 2025, for example, projects that the age-standardized prevalence rate of gout among older adults will rise to 3,628.85 per 100,000 population by 2050, confirming a sustained demand for effective management solutions. Concurrently, the escalating burden of chronic kidney disease (CKD) and metabolic disorders amplifies the necessity for hyperuricemia management, as elevated uric acid acts as both a complication and a potential progression factor for renal impairment. This urgency compels healthcare providers to prioritize aggressive urate monitoring and intervention in nephrology settings to prevent further kidney deterioration and manage cardiovascular risks. Scientific Reports, in November 2025, highlighted this critical overlap, revealing that 65.6% of non-dialysis chronic kidney disease patients presented with hyperuricemia. The commercial scale of this high-need segment is evidenced by Amgen's report in February 2025, stating that its targeted gout therapy, KRYSTEXXA, generated $1.2 billion in sales during 2024, demonstrating substantial market value in addressing severe and refractory cases.

Market Challenge

A primary impediment to the global hyperuricemia market's growth is the pervasive issue of poor patient adherence to chronic therapy, compounded by safety concerns associated with first-line medications. Despite an expanding potential patient base, the market's actual growth is significantly hindered because many individuals prematurely discontinue treatment. This high discontinuation rate often arises from the asymptomatic nature of hyperuricemia during inter-critical periods, which leads patients to underestimate the ongoing need for daily pharmacological intervention. Moreover, fears of toxicity, such as severe cutaneous reactions or cardiovascular risks linked to standard xanthine oxidase inhibitors, cause hesitation among both prescribers and patients, thereby limiting the volume of long-term prescriptions. This widespread lack of compliance directly impacts market performance by reducing prescription refills and diminishing the real-world efficacy of therapeutic agents. When treatment protocols are not sustained, patient outcomes stagnate, which prevents the widespread adoption of higher-value therapies. According to the American College of Rheumatology, 2025 survey data indicated that adherence to recommended dosing standards for urate-lowering therapy remains suboptimal, with less than 50% of treatment regimens fully aligning with the guidelines necessary to maintain target serum urate levels. This gap in effective utilization ensures that a substantial segment of the addressable market remains under-monetized, preventing the industry from fully capitalizing on the rising prevalence of the disease.

Market Trends

The treatment landscape is undergoing a significant transformation with the rapid emergence of novel selective URAT1 inhibitors, which are designed to address the efficacy limitations of existing xanthine oxidase inhibitors. Pharmaceutical developers are increasingly prioritizing high-potency uricosuric agents that directly target renal transporters to enhance uric acid excretion, offering a viable alternative for patients who fail to achieve target serum levels with standard oral therapies. This clinical shift is exemplified by the advancement of next-generation candidates engineered to maximize efficacy while minimizing renal toxicity. For instance, FierceBiotech reported in September 2025 that Atom Therapeutics' novel URAT1 inhibitor, ABP-671, achieved an impressive 91% response rate in reducing tophus diameter by week 28 in a pivotal Phase 2b/3 clinical trial. Simultaneously, there is a noticeable shift towards biologic combination therapies for refractory gout, specifically targeting the severe patient segment unresponsive to conventional oral medications. This trend involves integrating recombinant uricase enzymes with immunomodulatory technologies to mitigate anti-drug antibody formation and sustain therapeutic potency. These advanced regimens are crucial for rapidly reducing crystal deposits in chronic cases, thereby preventing irreversible joint damage. According to Pharmacy Times in January 2025, the novel combination therapy SEL-212 demonstrated a 56% response rate in maintaining serum urate levels below 6 mg/dL in high-dose cohorts, validating its potential to address significant unmet needs in the refractory setting.

Key Market Players

• Takeda Pharmaceutical Company Limited
• AstraZeneca plc
• Horizon Therapeutics plc
• Novartis AG
• Sanofi S.A.
• Teijin Pharma Limited
• Mylan N.V.
• Hikma Pharmaceuticals PLC
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd

Report Scope

In this report, the Global Hyperuricemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hyperuricemia Market, By Type

• Primary
• Secondary

Hyperuricemia Market, By Drug Type

• Xanthine Oxidase Inhibitors
• Nonsteroidal Anti-Inflammatory Drugs
• Corticosteroids
• Others

Hyperuricemia Market, By Route of Administration

• Oral
• Injectable

Hyperuricemia Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hyperuricemia Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hyperuricemia Market.

Available Customizations:

Global Hyperuricemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hyperuricemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Primary, Secondary)
  • 5.2.2. By Drug Type (Xanthine Oxidase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Others)
  • 5.2.3. By Route of Administration (Oral, Injectable)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Hyperuricemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hyperuricemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Hyperuricemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Hyperuricemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Hyperuricemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hyperuricemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Hyperuricemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Hyperuricemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Hyperuricemia Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Hyperuricemia Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Hyperuricemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hyperuricemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Hyperuricemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Hyperuricemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Hyperuricemia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Hyperuricemia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Hyperuricemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hyperuricemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Hyperuricemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Hyperuricemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Hyperuricemia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hyperuricemia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Hyperuricemia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Hyperuricemia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hyperuricemia Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Takeda Pharmaceutical Company Limited
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca plc
• 15.3. Horizon Therapeutics plc
• 15.4. Novartis AG
• 15.5. Sanofi S.A.
• 15.6. Teijin Pharma Limited
• 15.7. Mylan N.V.
• 15.8. Hikma Pharmaceuticals PLC
• 15.9. Dr. Reddy's Laboratories Ltd.
• 15.10. Sun Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer